Compare DexCom, Inc. (DXCM) vs Gold Fields Limited (GFI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
DexCom, Inc. vs Gold Fields Limited — how do they compare? DexCom, Inc. trades at $84.11 (market cap $31.86B), while Gold Fields Limited trades at $36.82 (market cap $31.87B). The key difference: DexCom, Inc. and Gold Fields Limited are close in size by market cap, and Gold Fields Limited pays a 6% dividend while DexCom, Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold DexCom, Inc. for 62 Days and Gold Fields Limited for 49 Days on average.
| DXCM | GFI | |
|---|---|---|
Market Cap | $31.86B | $31.87B |
Volume | 3,607,070 | 4,169,651 |
Sector | Health | Basic Materials |
52-Week High | $92.34 | $61.52 |
52-Week Low | $54.84 | $31.25 |
Typical Hold Time | 62 Days | 49 Days |
Enterprise Value | $31.32B | $32.47B |
Dividend Yield | — | 6% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DexCom (DXCM) trades at $84.41, showing modest daily gains of 0.13%. The stock demonstrates strong fundamental performance with consistent earnings beats and robust revenue growth, reaching $4.66 billion in 2025. Technical indicators show a bearish short-term trend with key support at $82. The company maintains impressive profitability with 20.12% net margins and 38.49% ROE, supported by growing adoption of CGM technology in diabetes care.
DXCM presents a compelling growth story with expanding market opportunities in Type 2 diabetes care. Analyst consensus remains strongly bullish with 81% buy ratings and $95.07 price target, suggesting 13% upside. Key risks include reimbursement challenges and competitive pressures. The company's strong cash flow generation and institutional support provide solid foundation for continued growth.
Gold Fields (GFI) trades at $35.86, up 2.31% today, amid a bearish technical signal but strong fundamentals. Revenue surged to $8.75B in 2025 with a net income margin of 38.66%, while valuation ratios like a P/E of 7.3 and EV/EBITDA of 4.64 suggest undervaluation. Recent news centers on a rejected $27B bid for Northern Star, causing volatility, but operational performance remains robust with record cash flow.
The outlook is mixed: analyst consensus is a Buy with a $52.75 price target, but technicals are bearish and earnings misses pose near-term risks. Upside hinges on execution of growth projects and gold price stability, while acquisition-related uncertainty and debt levels warrant caution for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About DexCom, Inc.
Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.
Read more on DXCM →About Gold Fields Limited
Gold Fields Ltd is a producer of gold and is a holder of gold reserves and resources in South Africa, Ghana, Australia and Peru. In Peru, the company also produces copper. The company is primarily involved in underground and surface gold and surface copper mining and silver and related activities, including exploration, extraction, processing and smelting. It conducts underground and surface mining operations at St. Ives, underground-only operations at Agnew, Granny Smith and South Deep and surface-only open pit mining at Damang, Tarkwa and Cerro Corona. The company's revenues are derived from the sale of gold that it produces.
Read more on GFI →
